V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009060 | 220003661 | 1.77 | 14.4 | Palliative (P) | 2016-06-12 | 2016-06-17 | CABOZANTINIB | N | N | 220035800 | CISPLATIN + ETOPOSIDE |
| 220009061 | 220003662 | 2 | 79.9 | Curative (C) | 2016-07-10 | 2016-07-10 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 2 | N | 220035811 | ATG + BUSULFAN + FLUDARABINE |
| 220009062 | 220003663 | null | 76 | Adjuvant (A) | 2013-08-10 | 2013-08-10 | CETUXIMAB | null | null | 220035815 | BEVACIZUMAB |
| 220009063 | 220003664 | 1.77 | 0 | Palliative (P) | null | 2015-03-01 | BOSUTINIB | N | N | 220035816 | CAPECITABINE + STREPTOZOCIN |
| 220009064 | 220003665 | null | null | Palliative (P) | 2016-03-18 | 2016-03-26 | ECarboX | null | null | 220035828 | VINCRISTINE |
| 220009065 | 220003666 | 1.65 | 52 | null | 2016-07-13 | 2016-07-26 | RUXOLITINIB | 02 | N | 220035832 | INTERFERON |
| 220009066 | 220003667 | 1.8 | 59.7 | Palliative (P) | 2013-08-04 | 2013-08-04 | Triple / Double Intrathecal Therapy | N | N | 220035834 | CAPECITABINE + STREPTOZOCIN |
| 220009067 | 220003668 | 1.56 | 74.6 | Palliative (P) | 2015-04-01 | 2015-06-28 | Y-90 | N | null | 220035837 | CHOP R |
| 220009068 | 220003669 | 1.74 | null | Palliative (P) | 2015-09-02 | 2015-09-28 | Methotrexate intrathecal | N | N | 220035839 | CETUXIMAB |
| 220009069 | 220003670 | 1.73 | null | Palliative (P) | 2015-12-05 | 2015-12-11 | VINCRISTINE | N | N | 220035840 | DOXORUBICIN |
| 220009070 | 220011989 | null | null | Palliative (P) | 2013-03-15 | 2013-03-15 | Cyclophosphamide TBI Allograft | Y | N | 220035843 | DACARBAZINE |
| 220009071 | 220011989 | 1.68 | 111 | Palliative (P) | null | 2018-09-01 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220035843 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009072 | 220011989 | 0 | null | Curative (C) | 2013-10-02 | 2013-10-10 | Irinotecan + Modified De Gramont | N | Y | 220035843 | TRIPLE INTRATHECAL |
| 220009073 | 220011989 | 1.61 | 74.8 | Palliative (P) | null | 2016-12-19 | Melphalan IV High dose | N | N | 220035843 | VINCRISTINE |
| 220009074 | 220011989 | 1.6 | -1 | Palliative (P) | 2013-08-29 | 2013-08-29 | Capecitabine | 02 | N | 220035843 | CAPECITABINE |
| 220009075 | 220011989 | 1.76 | 0 | Neo-adjuvant (N) | 2014-07-13 | 2014-07-19 | AML LI-1 Trial | N | N | 220035843 | FEC |
| 220009076 | 220003671 | 1.48 | null | Curative (C) | 2017-08-08 | 2017-09-08 | UKALL14- Ph 1 Induction | N | N | 220035856 | ARSENIC TRIOXIDE |
| 220009077 | 220003672 | 1.74 | 51.1 | Palliative (P) | 2014-03-09 | 2014-03-18 | UKALL14- Ph 1 Induction | N | N | 220035858 | CYTARABINE INTRATHECAL |
| 220009079 | 220011990 | null | 92.6 | Adjuvant (A) | 2013-08-09 | 2013-08-09 | Cisplatin | 2 | null | 220035861 | CARBOPLATIN + RT |
| 220009080 | 220003674 | 1.58 | 20.9 | Disease modification (D) | 2015-08-05 | 2015-08-05 | FLUOROURACIL + FOLINIC ACID | 01 | N | 220035866 | LI-1 TRIAL |
| 220009081 | 220003675 | 1.85 | null | Curative (C) | 2015-01-29 | 2015-01-30 | Thalidomide 50mg | N | N | 220035867 | FIGARO TRIAL |
| 220009082 | 220011991 | 1.77 | 93 | Curative (C) | 2019-02-20 | 2019-02-21 | Vemurafenib | 01 | N | 220035870 | CVP R |
| 220009083 | 220011991 | 1.55 | 76.6 | Curative (C) | 2017-04-24 | 2017-05-15 | IDARUBICIN + MITOXANTRONE + Tretinoin | 02 | N | 220035870 | FLA |
| 220009084 | 220003676 | 1.68 | 88.8 | Palliative (P) | 2014-10-18 | 2014-10-20 | Alemtuzumab(INTRAVENOUS) | 02 | N | 220035874 | RUXOLITINIB |
| 220009085 | 220003676 | 1.71 | 65 | Palliative (P) | 2014-05-22 | 2014-05-24 | Sunitinib | N | N | 220035874 | DABRAFENIB + TRAMETINIB |
| 220009086 | 220003677 | null | 49.1 | Curative (C) | 2015-02-11 | 2015-02-11 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 220035878 | FBC |
| 220009087 | 220003677 | null | 77.1 | Palliative (P) | 2014-10-13 | 2014-10-17 | SPIRIT 2 TRIAL | N | null | 220035878 | CISPLATIN + FLUOROURACIL |
| 220009088 | 220003677 | 1.7 | 77 | Palliative (P) | 2016-02-16 | 2016-02-17 | Cisplatin + Etoposide (3 day) | 02 | null | 220035878 | CETUXIMAB + IRINOTECAN + MDG |
| 220009089 | 220003678 | null | 60.5 | Not known (9) | 2013-09-12 | 2013-09-12 | Melphalan oral | 02 | Y | 220035885 | UKALL2014 |
| 220009090 | 220003678 | 1.73 | 95 | Palliative (P) | 2013-11-21 | 2013-12-01 | Cyclophosphamide High Dose | N | N | 220035885 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 220009091 | 220003679 | null | null | Palliative (P) | 2013-02-25 | 2013-02-26 | PACLITAXEL | null | null | 220035892 | PACLITAXEL |
| 220009092 | 220003679 | null | 84 | null | 2015-01-08 | 2015-01-08 | Bevacizumab+Carbo+Pacliaxel | 02 | Y | 220035892 | UKALL XII |
| 220009093 | 220003680 | 0 | 68 | Curative (C) | 2016-02-27 | 2016-02-27 | Folfirinox | 02 | N | 220035898 | SPIRIT TRIAL |
| 220009094 | 220003680 | null | 92.3 | Palliative (P) | 2015-12-30 | 2015-12-30 | Doxorubicin 75mg/m2 | null | N | 220035898 | IPILIMUMAB |
| 220009095 | 220003680 | null | 69.9 | Palliative (P) | 2016-10-03 | 2016-11-11 | Paclitaxel 7 day | N | N | 220035898 | PEMETREXED |
| 220009096 | 220003680 | 1.75 | null | Neo-adjuvant (N) | 2015-11-03 | 2015-11-04 | IDARUBICIN | N | N | 220035898 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009097 | 220003681 | 0 | 96 | Palliative (P) | 2014-06-26 | 2014-07-03 | BOSUTINIB | N | N | 220035911 | IRINOTECAN + MDG |
| 220009098 | 220003681 | null | null | null | 2014-11-23 | 2014-12-24 | Abiraterone | N | N | 220035911 | CISPLATIN + PEMETREXED |
| 220009099 | 220003681 | 1.79 | null | Adjuvant (A) | 2016-06-09 | 2016-06-09 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 99 | N | 220035911 | LANREOTIDE |
| 220009100 | 220003681 | 1.66 | 75.1 | Palliative (P) | 2014-04-15 | 2014-04-16 | CAPECITABINE + CARBOPLATIN | 2 | null | 220035911 | IPILIMUMAB |
| 220009101 | 220003681 | 1.52 | 63 | Palliative (P) | 2016-11-12 | 2016-12-06 | CVP R | N | N | 220035911 | LI-1 TRIAL |
| 220009102 | 220003682 | null | 78.6 | Palliative (P) | 2017-11-19 | 2017-11-19 | BOSUTINIB | 2 | null | 220035924 | CAPECITABINE + CISPLATIN |
| 220009103 | 220003682 | 0.62 | null | null | 2014-04-28 | 2014-05-01 | Cyclophosphamide High Dose | N | N | 220035924 | CAPECITABINE |
| 220009104 | 220003682 | 1.9 | 88.9 | Palliative (P) | 2015-08-27 | 2016-08-04 | DABRAFENIB + TRAMETINIB | N | N | 220035924 | DABRAFENIB + TRAMETINIB |
| 220009105 | 220019049 | 1.55 | 47.6 | Palliative (P) | 2015-02-15 | 2015-02-15 | UKALL14- Ph 1 Induction | N | N | 220035938 | CYTARABINE INTRATHECAL |
| 220009106 | 220019049 | 1.66 | 79 | Palliative (P) | 2015-03-27 | 2015-03-29 | Cisplatin +Fluorouracil (3 wk) | 02 | N | 220035938 | CAPECITABINE + CISPLATIN |
| 220009107 | 220019049 | 1.73 | 88.6 | Neo-adjuvant (N) | null | 2013-08-14 | Ipilimumab | N | N | 220035938 | BENDAMUSTINE + THALIDOMIDE |
| 220009108 | 220019049 | null | null | Disease modification (D) | null | 2016-01-03 | Fludarabine + Melphalan RIC Allo | Y | N | 220035938 | BORTEZOMIB |
| 220009109 | 220021786 | 1.73 | null | Palliative (P) | 2016-05-02 | 2016-05-07 | CISPLATIN + ETOPOSIDE | 2 | Y | 220035947 | CARBO + FLUOROURACIL |
| 220009110 | 220021786 | null | null | Palliative (P) | 2016-03-10 | 2016-03-16 | PACLITAXEL | null | null | 220035947 | CISPLATIN + FLUOROURACIL |